Dr. Rahul Bhargava — Principal Director Hematology at Fortis Memorial Research Institute
Verified Specialist
Senior Hematologist & BMT Expert

Dr. Rahul Bhargava

MBBS  ·  MD (Medicine)  ·  DM Clinical Hematology — AIIMS New Delhi
Principal Director & Chief — Hematology, Hemato-Oncology & Bone Marrow Transplant
Fortis Memorial Research Institute, Gurugram
Bone Marrow Transplant CAR T-cell Therapy Blood Cancer Stem Cell Transplant Thalassemia Hemophilia Aplastic Anemia
23+Years
Experience
1,500+Stem Cell
Transplants
3,000+Successful
Patients
4.7 / 5 ★(140)
Rating
120+Countries
Served
Get Treatment Plan Talk to Patient Support
Doctor will review your reports before recommending a treatment plan
23+ YearsClinical Hematology Experience
1,500+Bone Marrow / Stem Cell Transplants
>95%Transplant Success Rate
Blood DisordersBMT · CAR T · Blood Cancer · Thalassemia
───────────────────────────────────────────────────── -->
About the Doctor

About Dr. Rahul Bhargava

Dr. Rahul Bhargava is one of India's most distinguished hematologists, with over 23 years of dedicated experience in clinical hematology, hemato-oncology, and stem cell transplantation. He currently serves as Principal Director & Chief of Hematology at Fortis Memorial Research Institute, Gurugram — one of India's premier cancer and blood disorder centres.

Between 2011 and 2013, Dr. Bhargava pioneered the establishment of the first stem cell transplant centre at Medanta The Medicity in Gurgaon, placing India on the global map for haematological care. In 2016, he became the first Indian doctor to popularize stem cell transplants for multiple sclerosis (HSCT), a groundbreaking achievement that has since transformed lives across the country and beyond.

Driven by a vision of an anaemia-free and thalassemia-free India, Dr. Bhargava has set up 10 low-cost BMT centres across India — including Batra Hospital, Sarvodaya Hospital, and Action Balaji Hospital — partnering with government initiatives to make bone marrow transplants accessible to all sections of society.

He has completed his DM in Clinical Hematology from AIIMS New Delhi (2009), the most prestigious institution in Indian medicine, and has participated in over 1,000 Continuing Medical Education (CME) programs. In 2018, he screened over 500 children for blood disorders in schools across Haryana, reflecting his deep commitment to community health. Dr. Bhargava is an active member of the Delhi Hematology Society.

With 1,500+ bone marrow transplants and 3,000+ successfully treated patients from over 50 countries, Dr. Bhargava combines world-class expertise with a compassionate, patient-first approach that makes him the top choice for international patients seeking life-saving blood disorder treatment in India.

Education & Training

DM — Clinical HematologyAIIMS New Delhi  |  2009
MD — Internal MedicineBarkatullah University, Bhopal  |  2004
MBBSBarkatullah University, Bhopal  |  2001

Awards & Recognition

lMedAchievers Healthcare Icon AwardSignificant contributions in hematology & stem cell transplantation
Award for Excellence in HematologyPresented by Hon. Union Health Minister JP Nadda
Best Doctor AwardFor achievements & diligence in BMT Clinic
Pioneer — HSCT for Multiple SclerosisFirst Indian doctor to popularize stem cell transplant in MS (2016)
Why Dr. Bhargava

Why Choose Dr. Rahul Bhargava?

Decades of expertise, pioneering breakthroughs, and a proven record — here is why patients from 120+ countries trust Dr. Bhargava for blood disorder care.

1,500+Transplants
>95%Success Rate
120+Countries
01

India's Most Experienced BMT Specialist

Over 1,500 bone marrow and stem cell transplants — one of the highest volumes in Asia — with a >95% engraftment success rate.

02

Pioneer of HSCT for Multiple Sclerosis

First Indian doctor to popularize haematopoietic stem cell transplants for aggressive MS in 2016, changing lives globally.

03

Trusted by 120+ Countries

Dr. Bhargava's team has successfully guided patients from Nigeria, Iraq, Bangladesh, the UK, Ukraine, and 115+ more nations.

04

10 Affordable BMT Centres Across India

Set up low-cost transplant centres at Batra, Sarvodaya, Action Balaji and more — making curative BMT accessible to all.

05

AIIMS-Trained, Award-Winning Doctor

DM in Clinical Hematology from AIIMS New Delhi — India's top medical institute. Recipient of the MedAchievers Healthcare Icon Award and Best Doctor Award.

06

Personalised, Patient-First Care

Every case is personally reviewed by Dr. Bhargava. Treatment plans are tailored, transparent, and discussed in detail before travel.

Conditions & Specializations

Conditions Treated by Dr. Bhargava

Blood Cancer (Hematologic Malignancies)

Leukemia (AML, CML, CLL, ALL), Lymphoma (Hodgkin & Non-Hodgkin), Multiple Myeloma — treated with advanced chemotherapy, targeted therapy & stem cell transplant.

Bone Marrow Transplant (BMT)

Autologous, allogeneic, and haplo-identical BMT for leukemia, lymphoma, aplastic anemia, and inherited blood disorders. 1,500+ transplants performed.

CAR T-Cell Therapy

Cutting-edge immunotherapy using genetically modified T-cells to target blood cancers that have relapsed after standard treatments.

Thalassemia & Sickle Cell Disease

Curative BMT for major thalassemia and sickle cell anemia in children and adults. Low-cost BMT programs available across India.

Hemophilia & Bleeding Disorders

Comprehensive management of hemophilia A & B, Von Willebrand disease, platelet disorders, and other complex coagulopathies.

Aplastic Anemia

Both immunosuppressive therapy and stem cell transplantation for severe and very severe aplastic anemia, including pediatric cases.

Stem Cell Transplant for MS

Pioneer of HSCT (Hematopoietic Stem Cell Transplant) for Multiple Sclerosis in India — a disease-modifying treatment for aggressive MS.

Pediatric Hematology

Expert care for blood disorders in children including childhood leukemia, thalassemia, immune thrombocytopenia (ITP), and inherited bone marrow failure syndromes.

Myelodysplastic Syndrome (MDS)

Diagnosis and treatment of bone marrow failure and pre-leukemia syndromes with hypomethylating agents and allogeneic stem cell transplantation.

Procedures & Techniques

Procedures & Expertise

Allogeneic Bone Marrow Transplant (Allo-BMT)

The most complex and potentially curative form of BMT where stem cells come from a matched donor (sibling or unrelated). Used for leukemia, aplastic anemia, and inherited blood disorders.

  • HLA-matched sibling and unrelated donor transplants
  • Haplo-identical (half-match) transplants using parent or child donors
  • Reduced-intensity conditioning for older patients
  • Comprehensive GVHD prevention and management
Expected Outcome: Potential cure for blood cancers — long-term remission achieved in 60–80% of suitable patients
Autologous Stem Cell Transplant (Auto-SCT)

Patient's own stem cells are harvested, stored, and reinfused after high-dose chemotherapy. Primarily used in multiple myeloma and relapsed lymphomas.

  • Peripheral blood stem cell collection (PBSC)
  • High-dose melphalan for multiple myeloma
  • BEAM conditioning for lymphoma
  • Rapid recovery with minimal GVHD risk
Expected Outcome: Deepens remission and extends progression-free survival in myeloma and lymphoma patients
CAR T-Cell Therapy

Chimeric Antigen Receptor T-cell therapy — a revolutionary immunotherapy where the patient's own T-cells are genetically reprogrammed to attack cancer cells.

  • CD19-targeted CAR T for B-cell lymphomas and ALL
  • BCMA-targeted CAR T for relapsed/refractory multiple myeloma
  • Cytokine release syndrome (CRS) management
  • Available for patients who have relapsed after 2+ lines of therapy
Expected Outcome: Complete remission in 40–70% of relapsed/refractory blood cancer patients with no other options
HSCT for Multiple Sclerosis

Hematopoietic Stem Cell Transplantation (HSCT) for aggressive relapsing-remitting multiple sclerosis — resets the immune system to halt disease progression.

  • Patient selection based on EDSS score and MRI activity
  • Non-myeloablative conditioning to minimize risks
  • Pioneer centre in India for this procedure (since 2016)
  • Comprehensive neurology team collaboration
Expected Outcome: Halts or reverses disability progression in 70–80% of carefully selected MS patients
BMT for Thalassemia & Sickle Cell Disease

The only curative treatment for beta-thalassemia major and sickle cell disease through allogeneic stem cell transplantation from an HLA-matched sibling.

  • Best outcomes in Pesaro Class I & II patients (children with minimal organ damage)
  • Low-cost BMT programs available (10 centres across India)
  • Dedicated thalassemia transplant protocols
  • Vision of a thalassemia-free India
Expected Outcome: Disease-free survival of 85–90% in young children transplanted in Class I & II
Patient Voices

What Our International Patients Say

Measured Results

Clinical Outcomes & Success Metrics

>95% Transplant procedure success rate (engraftment achieved)
80–90% 2-year disease-free survival in thalassemia BMT
<3% 30-day treatment-related mortality in low-risk patients
14–21 days Average hospital stay for autologous SCT
50+ Countries whose patients have sought care from Dr. Bhargava
4.7 / 5 Average patient satisfaction (Google Reviews)
Free Consultation

Get Free Expert Opinion from Dr. Rahul Bhargava

Send your medical reports and get a personalised treatment plan from one of India's top hematologists — at no charge. Dr. Bhargava's team reviews cases from 120+ countries and responds within 24 hours.

  • Free second opinion on your diagnosis & reports
  • Detailed treatment plan with estimated cost
  • Full visa & travel assistance arranged
  • Dedicated coordinator assigned to your case
  • Airport pick-up & accommodation support
Get Free Doctor Opinion
Dr. Bhargava's team responds in 24 hrs
Your information is private & secure
Common Questions

Frequently Asked Questions

How many transplants has Dr. Bhargava performed?
Dr. Rahul Bhargava has performed over 1,500 bone marrow and stem cell transplants over his 23-year career, making him one of the most experienced BMT specialists in Asia.
What is the success rate for BMT at Fortis Gurugram?
Engraftment (transplant take) is achieved in over 95% of cases. Long-term disease-free survival depends on the underlying condition: 85–90% for thalassemia in young children, 60–80% for leukemia, and 70–80% for aplastic anemia.
How soon can I travel to India after initial contact?
After sharing your reports, we typically provide a treatment plan within 48 hours. Visa invitation letters are issued within 3–5 working days. Most international patients can travel within 2–3 weeks of initial contact.
Is a stem cell transplant for MS suitable for me?
HSCT for MS is generally suitable for patients with relapsing-remitting MS who are failing disease-modifying therapies, have active MRI lesions, and have an EDSS score below 6.0. Dr. Bhargava's team will evaluate your MRI, EDSS score, and treatment history to determine eligibility.
What languages does Dr. Bhargava's team communicate in?
The coordination team communicates in English, Hindi, and Arabic. Interpreters for other languages (French, Swahili, Bangla, Nepali) can be arranged. All medical reports can be submitted in English.
Does Fortis Gurugram accept international health insurance?
Yes, Fortis Memorial Research Institute works with major international insurers including Cigna, Aetna, BUPA, and Allianz. Our team handles insurance pre-authorization and cashless processing where possible.
Can family members stay with the patient during treatment?
Yes. For BMT patients (who are in isolation rooms), one caregiver can stay nearby. Partner hotels and service apartments are available within 10 minutes of the hospital at negotiated rates for patient families.
How do I get a second opinion from Dr. Bhargava?
Share your complete medical records (biopsy reports, bone marrow aspiration/biopsy, blood counts, imaging) via WhatsApp (+91 9990628827) or email (drrahulbhargava@yahoo.com). Dr. Bhargava's team will respond within 24–48 hours with a preliminary opinion.
What is CAR T-cell therapy and is it available in India?
CAR T-cell therapy is a revolutionary treatment where the patient's own immune T-cells are genetically re-engineered to target cancer cells. It is now available at Fortis Gurugram for relapsed/refractory B-cell lymphomas and multiple myeloma, at a fraction of the cost compared to the USA or Europe.
What post-treatment follow-up is provided for international patients?
Dr. Bhargava's team provides structured follow-up via tele-consultation, regular blood test monitoring, and coordination with local hematologists in your home country. Patients are given a detailed discharge summary and a follow-up protocol to share with their local doctors.

Get Treatment Plan from Dr. Rahul Bhargava

Share your reports and receive a personalised treatment recommendation within 48 hours — at no cost.

Upload Reports WhatsApp Now Call +91-999-973-6555
Get Doctor Opinion Book Appointment